Knowledge about human papillomaviruses (HPV) types involved in anal cancers in some world regions is scanty. Here, we describe the HPV DNA prevalence and type distribution in a series of invasive anal cancers and anal intraepithelial neoplasias (AIN) grades 2/3 from 24 countries. We analyzed 43 AIN 2/3 cases and 496 anal cancers diagnosed from 1986 to 2011. After histopathological evaluation of formalin-fixed paraffin-embedded samples, HPV DNA detection and genotyping was performed using SPF-10/DEIA/LiPA 25 system (version 1). A subset of 116 cancers was further tested for p16 INK4a expression, a cellular surrogate marker for HPV-associated transformation. Prevalence ratios were estimated using multivariate Poisson regression with robust variance in the anal cancer data set. HPV DNA was detected in 88.3% of anal cancers (95% confidence interval [CI]: 85.1-91.0%) and in 95.3% of AIN 2/3 (95% CI: 84.2-99.4%). Among cancers, the highest prevalence was observed in warty-basaloid subtype of squamous cell carcinomas, in younger patients and in North American geographical region. There were no statistically significant differences in prevalence by gender. HPV16 was the most frequent HPV type detected in both cancers (80.7%) and AIN 2/3 lesions (75.4%). HPV18 was the second most common type in invasive cancers (3.6%). p16 INK4a overexpression was found in 95% of HPV DNA-positive anal cancers. In view of the results of HPV DNA and high proportion of p16 INK4a overexpression, infection by HPV is most likely to be a necessary cause for anal cancers in both men and women. The large contribution of HPV16 reinforces the potential impact of HPV vaccines in the prevention of these lesions.
Anal carcinomas are relatively rare, with about 27,000 new cases diagnosed worldwide in 2008 and age-adjusted incidence rates around 1 per 100,000 population. 1, 2 However, recent reports indicate increasing incidences in some developed countries linked to several factors such as changes in sexual behavior. [3] [4] [5] Men having sex with men, particularly those infected by human immunodeficiency virus (HIV), represent a high risk group for the development of anal cancer. [6] [7] [8] HIV-infected women also have a high risk of developing anal intraepithelial neoplasia (AIN) and invasive anal cancer. 8, 9 Few case-control studies have evaluated the association between human papillomaviruses (HPVs) and anal cancer reporting odds ratios between 2 and 7 for HPV16 and HPV18 seropositivity for both men and women. 10 In addition, one case-control study that evaluated the presence of the virus in tumor tissue found a higher viral detection among anal carcinomas (88%, 340/388) than rectal adenocarcinomas (0%, 0/ 20). 11 Among HPV-related cancers, anal cancer has been linked to HPV with the highest deoxyribonucleic acid (DNA) detection rates just after cervical cancer. HPV DNA prevalence has been estimated at 94% in AIN grades 2/3 and 88% in anal cancer, with HPV16 the most frequent HPV type identified. 1, 12 Information on anal cancer HPV type distribution is lacking in some world regions with most of the published reports coming from United States of America (USA) and Europe. 12 Such information is crucial to estimate the impact of HPV prophylactic vaccines in the reduction of anal cancer burden from a global perspective, particularly now that we have evidence for efficacy of HPV vaccines in the prevention of AIN and anal HPV persistent infection by types included in the vaccines. 13 Our study aims to describe the HPV DNA prevalence and type distribution in a series of 539 AIN 2/3 and anal cancers from 24 countries. To our knowledge, and despite the underrepresentation of certain geographical regions, the data reported in this article represent the largest international effort to assess the role of HPVs in anal cancer using a standard protocol with a high sensitive HPV DNA detection test together with p16 INK4a expression evaluation, a cellular surrogate marker for HPV-associated transformation.
Material and Methods

Study design
A retrospective cross-sectional study was designed and coordinated by the Institut Catal a d'Oncologia (ICO), Barcelona,
What's new?
Human papillomavirus (HPV) is linked to anal cancer through high HPV DNA-detection rates. Here, in one of the largest international studies to date, HPV DNA was detected in more than 88% of anal cancers and more than 95% of anal intraepithelial neoplasias grades 2/3. HPV16 was the most frequently detected virus type, followed by HPV18. Overexpression of p16 INK4a ,a surrogate marker for HPV-associated transformation, was found in 95% of HPV-positive anal cancers. The data implicate HPV as a causative factor in anal cancer.
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Spain, and DDL Diagnostic Laboratory, Rijswijk, The Netherlands, to estimate the HPV DNA prevalence and type distribution in patients with AIN 2/3 and invasive anal cancers diagnosed from 1986 to 2011. Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from pathology archives in 24 countries: Europe (Bosnia-Herzegovina, Czech Republic, F r a n c e ,G e r m a n y ,P o l a n d ,P o r t u g a l ,S l o v e n i a ,S p a i na n dU n i t e d Kingdom); North America (USA); Latin America (Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico and Paraguay); Africa (Mali, Nigeria and Senegal); Asia (Bangladesh, India and South Korea) and Oceania (Australia). Centers were requested to provide non selected series of cases from their archives preferably consecutive in time. Information about age at and year of diagnosis, gender and original histological diagnosis was also obtained from the participating centers.
Histopathological evaluation
FFPE tissue blocks were processed under strict conditions to avoid potential contamination as described in a previous publication. 14 At least four FFPE sections were obtained from each block using the sandwich method. First and last sections were used for histopathological evaluation after hematoxylin and eosin (HE) staining. The intermediate sections were used for HPV DNA testing. The laboratory at ICO processed the FFPE tissue blocks and reviewed the resulting HE slides. The latter was performed by following the consensus criteria established by an expert panel of pathologists based on the WHO classification of the digestive system. 15 The pathology evaluation included several items such as histological diagnosis, tumor subtype and adequacy of the sample for further HPV testing. Adenocarcinomas and basal-cell carcinomas were excluded from the study as most of the adenocarcinomas likely represent a downward spread from adenocarcinomas of the rectum and basal cells arise from skin epithelium, being both HPV-unrelated types of lesions. 10, 12 To confirm the non HPV relationship of the adenocarcinomas received and to support the exclusion criteria decision, a subset of more than 50% of these cases were processed and HPV was analyzed. Only two cases out of the 62 adenocarcinomas (HPV DNA analyzed) were positive for viral presence (3%), supporting the non HPV association of these tumors. A block was determined to be adequate for further HPV DNA testing if invasive cancer or an AIN 2/3 lesion was observed in the two HE-stained sections of the specimen. In case of discrepancies between the histologic diagnosis in local and in the reference pathology laboratories, the cases were re-evaluated and the results obtained at the reference lab prevailed. To control for possible sources of contamination, blocks containing non HPV-related tissues processed in the local pathology lab at the same time as the anal specimens under study were blindly processed (5% of the total anal cases).
HPV DNA detection and typing
For each specimen, a paraffin tissue section was digested with 250 mL of proteinase K solution (10 mg/mL proteinase K in 50 mM Tris-HCI, pH 8.0) to release DNA. Short PCR fragment (SPF)210 polymerase chain reaction (PCR) was performed in a final reaction volume of 50 mL using 10 mLo f extracted DNA (dilution, 1:10). The amplified PCR products were tested for the presence of HPV DNA using a DNA enzyme immunoassay (DEIA) as described previously. 16, 17 DEIA can recognize at least 54 HPV types. Amplimers testing positive by DEIA for viral DNA were used to perform the reverse hybridization line probe assay (LiPA 25 ) (version 1: produced at Laboratory Biomedical Products, Rijswijk, The Netherlands). The LiPA 25 detection system allows for genotyping of 25 HPVs categorized by the IARC within the Group 1 (HPV16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58 and 59), Group 2A (HPV68), Group 2B (HPV34, 53, 66, 70 and 73), Group 3 (HPV6 and 11), as well as other HPVs (HPV40, 42, 43, 44, 54 and 74). 10 All these types belong to nine species within Alphapapillomaviruses. The sequence variation within the SPF-10 interprimer region allows the recognition of these different HPV types, except for types 68 and 73, as their interprimer regions are identical and cannot be distinguished by LiPA 25 . Specimens testing positive for HPV DNA by DEIA but that could not be typed by LiPA 25 were further analyzed by direct Sanger sequencing of PCR products as described by Geraets et al. 18 The cases that could not be sequenced were labeled as "HPV undetermined". Further, specimens with an inconclusive probe line pattern by LiPA 25 (i.e., HPV68/73 or HPV39/68/73) were also sequenced to distinguish the specific HPV types. To evaluate the quality of DNA, all HPV DNA-negative samples were subjected to a PCR, targeting the human tubulin gene (forward primer: TCCTCCACTGGTACACAGGC; reverse primer: CATGTT GCTCTCAGCCTCGG), which generated a 65-bp amplicon, the same size as the SPF-10 amplicon used for assessing the presence of HPV DNA. Samples that were both negative for HPV DNA and tubulin were considered to be of inadequate quality and were therefore excluded from the final analyses.
p16 INK4a expression
The evaluation of immunohistochemical p16 INK4a expression was performed in all HPV DNA-negative invasive anal cancer cases with available material and in a random selection of HPV-positive cases (total, n 5 116). p16 INK4a was detected using the CINtec histology kit (clone E6H4, Roche mtm laboratories AG, Germany) by following the manufacturer's protocol. A pattern of diffuse staining of more than 25% stained cells (nuclear and cytoplasmic staining) was considered positive. 19, 20 
Statistical analysis
Available information for the statistical analysis was as follows: country, age at and year of diagnosis, gender, histopathological diagnosis, the presence of HPV DNA, HPV type and the expression of p16 INK4a . Histological subtypes in anal cancers were grouped into the following categories: squamous cell carcinomas (SCC) 100% warty-basaloid (included exclusively or combinations of warty, basaloid or papillary basaloid histologies), SCC 100% non warty-basaloid (SCC without warty-basaloid morphological features), SCC mixed histologies (mix of the previous histological subtypes), other (undifferentiated, poorly differentiated, neuroendocrine and adenosquamous carcinomas).
The prevalence of HPV DNA and HPV type specific detection percentages was determined according to the geographical regions, histopathological categories, gender, patient's age at diagnosis and year of diagnosis. Prevalence ratios (PRs) were estimated using bivariate and multivariate Poisson regression models with robust variance. 21 In the final model, we included region, year of and age at diagnosis and gender. Histological diagnosis was not included in the regression analysis as it was considered as an intermediate variable in the carcinogenic process. The best fitting model was selected based on the log-likelihood ratio test. PRs were estimated only for anal cancers because AIN 2/3 subset of cases was small and showed a high HPV DNA detection rate (only two cases out of 43 AIN 2/3 were HPV DNA negative).
The prevalence of HPV DNA was estimated among finally included cases and HPV type specific relative contribution was calculated among the HPV DNA-positive cases. Multiple infections were added to single types under a weighting attribution proportional to the detection found in cases with single types as described previously. 14 To evaluate the increase or decrease on HPV type specific relative contributions between type of lesions, relative contribution ratios and their 95% confidence intervals (CI) were estimated (ratio of type specific relative contribution: percentage of a specific type in anal cancer/percentage of the same type in high-grade preneoplastic lesions).
Agreement between HPV DNA detection and p16 INK4a expression was assessed by Kappa score. The McNemar test for matched pair data was used for assessing unequal distribution of discordant results.
Statistical significance for all analyses was set at the twosided 0.05 level. Data analyses were performed with the Statistical Package for the Social Sciences (SPSS) version 13.0 (SPSS, Chicago, IL) and with STATA version 10.0 (Stata, Computing Resource Center, College Station, TX).
Ethical consideration
Specimens were received anonymously and allocated a unique identification number upon reception. All protocols were approved by international and ICO ethics committees and study progress was overseen by an international steering committee specifically formed for the supervision and advising in critical issues of the project.
Results
Initially, 784 FFPE tissue samples were collected. From these, 65 samples were non HPV-related tissues and used for contamination control; and 180 cases were excluded from the analyses: 169 were not suitable for HPV DNA testing based on the pathological criteria (e.g., non preinvasive or invasive lesion observed, adenocarcinomas and basal cell carcinomas, among others) and 11 cases were finally excluded for inadequate DNA quality, being both HPV DNA and tubulin negative ( Fig. 1 ). Therefore, 43 AIN 2/3 cases and 496 invasive anal cancers were included in the final analysis.
Patients with an AIN 2/3 diagnosis were approximately 12 years younger than patients diagnosed with an anal cancer (mean age at diagnosis, 50.8 years [standard deviation, SD 5 15.8] for AIN 2/3 vs. 62.8 [SD 5 14.7] for invasive cancer cases [p < 0.001]). Two-thirds of both preneoplastic and invasive cancer cases occurred in females (Table 1) . There was a higher representation from European and Latin American countries and from 2000 to 2011 time period of diagnosis. Warty-basaloid SCC histological type accounted for 58.5% of the anal cancers, being basaloid the most common subtype identified in this category (76.2%) ( Table 2 ). Less frequently, we identified non warty-basaloid SCC (33.3%), mixed warty-basaloid and non warty-basaloid histological SCC cases (6.0%) and "other" diagnoses (2.2%; 11 cases: four 
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undifferentiated, one poorly differentiated, three neuroendocrine and three adenosquamous tumors).
HPV DNA positivity was 95.3% (95% CI: 84.2-99.4%) for AIN 2/3 and 88.3% (95% CI: 85.1-91.0%) in invasive anal cancer (Table 1) . Within invasive cancer cases, HPV prevalence varied by geographical region with the highest prevalence in North America (95.8%; 95% CI: 89.7-98.9%) and the lowest in Africa (61.9%; 95% CI: 38.4-81.9%). No statistically significant differences were observed for gender or for period of diagnosis, neither in a 10-year nor in a 5-year period. Patients with anal cancer positive for HPV DNA were diagnosed at a younger age than patients with HPV-negative tumors (age, 62.2 years; SD 5 14.3 vs. 66.9, SD 5 17.0; p 5 0.027); there was a decreasing HPV DNA detection with increasing age at diagnosis (p-trend test 5 0.016). HPV prevalence varied according to the histological diagnosis ( Table 2) . Warty-basaloid SCC cases showed the highest HPV prevalence (95.9%; 95% CI: 92.9-97.8%) with no variation within the different histological subtypes included in this category, whereas the "other" histology category showed the lowest prevalence (27.3%; 95% CI: 6.0-61.0%). The three HPVpositive cases among the "other" category were one undifferentiated carcinoma, one neuroendocrine and one adenosquamous cell carcinoma. Among HPV DNA-positive samples (Table 3) , the percentage of multiple infections was higher for AIN 2/3 (22.0%) than for invasive anal cancers (7.3%) (p 5 0.005). The most frequent HPV type was HPV16 for both AIN 2/3 (75.4% including multiple infections) and invasive anal cancer (80.7%). Among cancers, the second most common type was HPV18 (3.6%), accounting together with HPV16 for 84.3% of HPV DNA-positive cases. Other HPV types detected were HPV33 (2.7%), HPV31 (1.9%), HPV6 and HPV58 (both 1.8%), HPV35 (1.6%), and other types were identified in <1.5% of the specimens. Figure 2 shows the relative contribution of HPV16, HPV18 and other types, displayed by region, time at and age of diagnosis, gender and histology (Supporting Information Tables 1-5; there is the complete type distribution by the available information). We observed a higher proportion of types other than HPV16/ HPV18 in Africa, and in males; but none of these comparisons were statistically significant.
Concordance between the expression of p16 INK4a and the presence of HPV DNA was observed in 87.1% of anal cancer cases analyzed (95% CI: 79.6-92.6%); with a Kappa score of 0.741 (95% CI: 0.620-0.862, p < 0.001), indicating substantial agreement. The McNemar test indicated that the discordant results were not equally distributed (p 5 0.039). The discordant pairs of HPV DNA-negative and p16 INK4a -positive cases were more frequent than the HPV DNA-positive cases with a p16 INK4a -negative result 
Discussion
I no u rs t u d y ,w eh a v ea n a l y z e dt h ep r e s e n c eo fH P VD N A in more than 500 precancerous and cancerous anal lesions collected across the five continents. A very high prevalence of HPV DNA was observed in both precancerous anal lesions and in invasive anal cancer at a similar magnitude to that observed in a meta-analysis on HPV detection in cervical cancer 22 and in our own previously published series on cervical cancer lesions. 14 In addition, p16 INK4a , a cellular surrogate marker for HPV-associated transformation, was overexpressed in almost all the HPV DNA-positive cancer cases evaluated (95%), confirming the etiological involvement of the detected HPVs in the carcinogenic process. This p16 INK4a overexpression figure resembles also that f o u n di no u ro w ns e r i e so nc e r v i c a lc a n c e rl e s i o n s( 9 8 % ) . 23 The most important individual contributor was HPV16 in both types of lesions. Overall, the HPV DNA positivity in AIN 2/3 cases was 95.3%, which is similar to that reported in a previous metaanalysis from de Vuyst et al., 12 (93.9%). In previous studies, HIV-positive individuals showed higher HPV DNA detection and different type distributions, with more multiple infections and lower proportion of HPV16, than HIV negative. 12 Unfortunately, the small sample size for the precancerous lesions in our study (43 cases) precluded any further investi-gation using the available information and information on HIV status was not available in the analyzed series.
Regarding invasive anal cancer, HPV DNA prevalence was 88.3% which was in accordance with a recent report on 146 anal cancers from USA (91.1%) 24 ; but higher than results from the meta-analysis from de Vuyst et al. (84.3%) and lower than the results obtained in large studies such as EDiTH V study (n 5 366, France) in which 97% of cases were HPV DNA positive. 12, 25 Our higher viral DNA detection rate compared to the meta-analysis could be attributed to the variability in material and methods in the included reports. Some studies in the systematic review used typespecific assays targeting a smaller set of HPVs than broadspectrum SPF-10 PCR, which could explain the lower detection rate. In addition, we performed a systematic pathological review of all cases and excluded potential HPV-unrelated diagnoses, such as the adenocarcinomas to avoid potential misclassification with rectal adenocarcinomas. Our lower detection compared to the EDiTH V study could be explained by our assessment of DNA quality targeting through PCR a small portion of the human tubulin gene, of precisely the same size as the HPV DNA target of the SPF-10 (65 bp). In contrast, in the EDiTH V study, a larger amplicon was used as a reference gene to assess the quality of DNA (HLA-DPB1, 270 bp). 25 The use of longer amplicons increases the probability of labeling a FFPE sample as not suitable for DNA assays, and thus excluding it from the denominator in rate estimations. As observed in other HPV-related cancers, we found a higher prevalence of viral DNA in warty-basaloid anal cancers. 12 Significant differences were also found between SCC and "other diagnosis" for which the HPV prevalence was lower. However, the low number of samples labeled as "other diagnosis" precluded establishing any conclusion. The prevalence of HPV was higher among the patients diagnosed with anal cancer at a younger age, which has also been observed in other HPV-related cancers. 14, 26 Some geographical differences were observed, with a noteworthy lower HPV prevalence in anal cancer specimens from Africa. There is not a clear explanation for this finding and technical reasons cannot be discarded. A report on HPV detection in anal cancers from six countries using HPV16 DNA hybridization also found a lower viral presence in specimens from South Africa and India than from Swiss, Polish or Brazilian cases. 27 Finally, although a higher HPV detection in women than in men was observed, the difference was not statistically significant. Such lack of difference on the prevalence of HPV in anal cancer by gender has also been observed in another recent report 24 ; however, other previous reports have observed a statistically significant higher HPV prevalence in women than men. 12 Regarding samples positive for HPV DNA, the most frequent type in AIN 2/3 was HPV16 with a prevalence of 75.4%. In invasive anal cancer, frequently found types were in decreasing order: HPV16 (80.7%), HPV18 (3.6%), HPV33 (2.7%), HPV31 (1.9%), HPV6 and HPV58 (both 1.8%) and HPV35 (1.6%). Our findings are in agreement with other reports in which HPV16 has been identified as the predominant HPV type in anal cancer, with a relative contribution among HPV DNA-positive cases that is much higher than in other anogenital HPV-related sites. 12, 14, [24] [25] [26] This increased contribution of HPV16 in anal cancer compared to other anatomic sites may have a biological basis, reflecting a differential tropism of HPV16 toward anal mucosa, a differential mucosal immune response or a differential increased probability of that type to lead to malignant transformation in the anal mucosa. HPV18 and HPV45, which are commonly overrepresented in glandular lesions, showed lower relative contributions than observed in cervical cancer tissue. 14, 22 This observation in anal compared to cervical lesions might be explained by the exclusion of glandular lesions from the study to avoid misclassification with rectal adenocarcinomas. In the stratified analysis by geographical region, we observed a higher proportion of types other than HPV16/HPV18 in Africa, but these observed differences were based on small number of cases (13 HPV DNA-positive cases in Africa) and were not statistically significant.
It is important to highlight that the detection rates of lowrisk HPV types (e.g., HPV6 and HPV11) were higher in anal cancer (1.8 and 1.1%, respectively) compared to those observed in cervical cancers (below 1% for both types). The increased prevalence of these types in the anal region is consistent with the high prevalence of warts at this anatomic site. From our sample series, a subset of four anal cancer cases harboring single low-risk infections (three HPV6 and one HPV42) was further analyzed by laser capture microdissection. In all four cases, DNA for these specific HPVs was found in tumor cells, and thus confirming the initial detection in the whole tissue section and excluding potential contamination from adjacent tissue. 28 Other investigators have also identified by laser capture microdissection HPV6 specifically in anal tumor cells. 29 Thus, our results confirm that low-risk types can be occasionally associated with invasive anal neoplastic lesions.
Twenty-two percent of AIN 2/3 cases harbored HPV DNA from multiple HPV types compared to 7.3% in anal cancers. This decrease in multiplicity of infection with neoplastic disease progression has been also described for CIN 2/3 (cervical intraepithelial neoplasia) and cervical cancer, 30 and may reflect the concept of clonal development of invasive neoplasia resulting from persistent infection with a single HPV type. 31, 32 The accumulated knowledge on the natural history of anal cancer closely resembles that of cervical cancer. Both types of tumors share similar transmission mechanisms for HPVs as etiological agents, are modulated by similar risk factors and seem to arise from the same type of cells occurring at a transition zone between columnar-glandular and stratified epithelia. This squamous-columnar junction may thus represent a susceptible spot in which the HPVs target cells that could be more prone to be transformed upon infection, leading to malignant transformation. Recently, a report identified that carcinogenic HPV-related cervical intraepithelial lesions and cervical cancers are linked to a small cell population localized at the squamous-columnar junction of the cervix that expresses a unique gene expression profile, and that is not regenerated after excision. 33 The determination of whether the anal cancers arise from a similar kind of cell population remains unknown and deserves further investigation. In addition, in the anal canal there could be an increased access of the virus to the basal cells linked to microlesions resulting from receptive intercourses. Our finding that p16 INK4a was overexpressed in almost all the HPV DNA-positive anal cancer cases analyzed (95%), resembles the figure found in our own cervical cancer series (98%) 23 and strongly points towards an etiological implication of the virus in the oncogenic process as it has been stated by others in the previous reports. 34, 35 Overexpression of p16 INK4a is detected in HPV-associated tumors but nearly absent in HPV-unrelated carcinomas. The biological link between HPV and p16 INK4a overexpression originates through the interaction of the viral oncoprotein E7 with the pRb protein, and is therefore a Infectious Causes of Cancer cellular surrogate marker of the causal link between viral infection and cancer. 36 The added value of our study compared to the previous reports is the use of highly sensitive HPV DNA detection and genotyping system (SPF-10/DEIA/LiPA 25 )u n d e rat h o r o u g h contamination control process; the processing and testing for HPV DNA in a single central laboratory with long standing experience with archival clinical specimens; the use of a DNA quality control PCR that generates an amplicon with the same length as the one used for viral DNA; the addition of a surrogate marker of HPV-associated cellular transformation (p16 INK4a ), suggesting the etiological involvement of the detected HPVs; and the detailed pathological evaluation performed to exclude potential HPV-unrelated misclassified diagnosis (like rectal adenocarcinomas). In addition, despite the under-representation of certain geographical regions, our data represent, to our knowledge, the largest international effort evaluating the involvement of HPVs in anal cancer under a common protocol.
Conclusions
In our study, we observed a major contribution of HPV to anal precancerous and cancerous lesions strongly suggesting the necessary role of HPV in the etiology of anal cancers as it has been reported previously. 34, 35 T h em o s tc o m m o nt y p ei nA I N 2/3 and in invasive anal cancers was HPV16, followed to a lesser extent by HPV18, which altogether accounted for 84.3% of HPV DNA-positive anal cancer cases. Our results suggest that both women and men would benefit from HPV vaccination and anal HPV screening for high risk groups to prevent anal cancerous lesions. HPV vaccination with currently licensed HPV prophylactic vaccines could potentially prevent 84.3% of the anal cancers and 75.4% of AIN 2/3 lesions.
